Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

Tenofovir is superior to entecavir in reducing HCC for patients with HBV-related compensated cirrhosis at high HCC risk scores

Background: Both tenofovir disoproxil fumarate (TDF) and entecavir (ETV) are known to reduce the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). This study aimed to compare the difference in HCC risk reduction between TDF and ETV in treatment-naïve patients with C...

Full description

Bibliographic Details
Main Authors: Chen, L. (Author), Gui, H. (Author), Huang, R. (Author), Huang, Y. (Author), Jiang, J. (Author), Lian, J. (Author), Liu, C. (Author), Liu, L. (Author), Qian, Y. (Author), Shang, J. (Author), Xie, Q. (Author), Zhu, C. (Author)
Format: Article
Language:English
Published: SAGE Publications Ltd 2022
Subjects:
chronic hepatitis B
compensated cirrhosis
entecavir
hepatocellular carcinoma
modified PAGE-B score
risk scores
tenofovir disoproxil fumarate
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items